SCHEMBL3897948

SCHEMBL3897948

NC(=O)NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
MTOR P42345 2/20 0.56
LSS P48449 1/20 0.55
HDAC3 O15379 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
NAMPT P43490 1/20 0.53
MAPK14 Q16539 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
KIF11 P52732 1/20 0.50
EPHX2 P34913 2/20 0.49
PPARG P37231 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576236 0.86 MTOR (0.54) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL24575984 0.85 MTOR (0.69) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL1695141 0.83 MTOR (0.58) CYP2C9CYP2C19MTORLSSHDAC3
SCHEMBL3428043 0.81 ALDH1A1 (0.54) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL21387743 0.81 HDAC3 (0.59) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL2629356 0.81 LSS (0.59) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL4020664 0.81 IDO1 (0.56) MTORLSSHDAC3HDAC1HDAC2
SCHEMBL4874599 0.81 MTOR (0.58) CYP2C9CYP2C19MTORIDO1RPS6KB1
SCHEMBL2827305 0.81 EPHX2 (0.69) CYP2C9CYP2C19HDAC3HDAC8HDAC6
SCHEMBL15682657 0.81 MTOR (0.52) MTORLSSHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725238-A4 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2009-04-01 EP claimed
EP-1725238-A2 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-29 EP claimed
CN-1863777-A Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2006-11-15 CN claimed
WO-2005094251-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-10-13 WO claimed
CN-113677334-B Transient receptor potential MELASTATIN 8 (TRPM 8) antagonists and related methods 马歇尔大学科研协会 2024-04-09 CN disclosed
EP-3265445-B1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-05-05 EP disclosed
WO-2013108026-A1 THIADIAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF DIABETES BALTIC BIO AB (SE) 2013-07-25 WO disclosed
WO-2013108026-A1 THIADIAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF DIABETES BALTIC BIO AB (SE) 2013-07-25 WO disclosed
EP-1725238-A4 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LTD (GB) 2009-04-01 EP disclosed
WO-2007123818-A2 ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2007-11-01 WO disclosed
EP-1725238-A2 M 3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-11-29 EP disclosed
CN-1863777-A Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2006-11-15 CN disclosed
WO-2005094251-A2 M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-10-13 WO disclosed
CN-1478084-A Compounds useful in treatment of inflammatory diseases 2004-02-25 CN disclosed